All articles by RanjithKumar Dharma
RanjithKumar Dharma
Study demonstrates Xylyx Bio’s Matrikynes is safe for skin improvement
The study has proved its efficacy for anti-ageing and other topical skin applications.
Alterity Therapeutics doses first patient in Phase II MSA trial of ATH434
The effect of ATH434 treatment on neuroimaging and protein biomarkers is being assessed in the study.
ContraFect begins Phase Ib/II clinical trial of exebacase
The randomised, double-blind and placebo-controlled clinical trial is to be carried out in France.
FibroGen completes patient enrolment in pamrevlumab trial
Fibrogen enrolled 372 patients in the trial, which will assess the efficacy and safety of pamrevlumab in patients with IPF.